Last updated on February 2020

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Brief description of study

This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).

Clinical Study Identifier: NCT04058353

Find a site near you

Start Over

Indiana University

Indianapolis, IN United States
  Connect »

University of Kentucky

Lexington, KY United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

Stanford University

Palo Alto, CA United States
  Connect »

National Jewish Health

Denver, CO United States
  Connect »

UC Health Holmes

Cincinnati, OH United States
  Connect »

Texas Children's Hospital

Houston, TX United States
  Connect »

Alfred Hospital

Melbourne, VIC, Australia
  Connect »

Mater Adult Hospital

South Brisbane, Australia
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Michigan Medicine

Ann Arbor, MI United States
  Connect »

Mount Sinai Beth Israel

New York, NY United States
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

Wythenshawe Hospital

Manchester, United Kingdom
  Connect »

UMC St. Radboud

Nijmegen, Netherlands
  Connect »